Article info
Clinical science
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
- Correspondence to Dr Brian L VanderBeek, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; brian.vanderbeek{at}pennmedicine.upenn.edu
Citation
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
Publication history
- Received March 10, 2021
- Accepted August 6, 2021
- First published August 19, 2021.
Online issue publication
January 20, 2023
Article Versions
- Previous version (20 January 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.